Entinostat, a member of the benzamide group, is a narrow-spectrum HDAC inhibitor and affects class I HDAC with limited effect on HDAC 8, which is already used for conducting several phase I/II clinical trials on cancers (Kiany et al., 2020). This evidence concerns the gene HDAC9 and cancer.